JP2017158561A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017158561A5 JP2017158561A5 JP2017077422A JP2017077422A JP2017158561A5 JP 2017158561 A5 JP2017158561 A5 JP 2017158561A5 JP 2017077422 A JP2017077422 A JP 2017077422A JP 2017077422 A JP2017077422 A JP 2017077422A JP 2017158561 A5 JP2017158561 A5 JP 2017158561A5
- Authority
- JP
- Japan
- Prior art keywords
- inflammatory
- seq
- composition according
- composition
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims 7
- 230000003110 anti-inflammatory effect Effects 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 239000002537 cosmetic Substances 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
Applications Claiming Priority (12)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2012-0079096 | 2012-07-20 | ||
| KR1020120079096A KR20140012385A (ko) | 2012-07-20 | 2012-07-20 | 항염증 활성을 갖는 펩티드 및 이를 포함하는 염증질환 치료용 조성물 |
| KR10-2012-0089162 | 2012-08-14 | ||
| KR10-2012-0089161 | 2012-08-14 | ||
| KR20120089161 | 2012-08-14 | ||
| KR10-2012-0089167 | 2012-08-14 | ||
| KR1020120089162A KR20140022698A (ko) | 2012-08-14 | 2012-08-14 | 텔로머라제 펩티드를 포함하는 염증 예방 또는 억제용 조성물 |
| KR1020120089167A KR20140022699A (ko) | 2012-08-14 | 2012-08-14 | 텔로머라제 펩티드를 포함하는 염증 예방 또는 억제용 조성물 |
| KR20120104207 | 2012-09-19 | ||
| KR10-2012-0104144 | 2012-09-19 | ||
| KR10-2012-0104207 | 2012-09-19 | ||
| KR20120104144 | 2012-09-19 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015521997A Division JP6352911B2 (ja) | 2012-07-20 | 2013-03-15 | 抗炎症活性を有するペプチド、及びそれを含む組成物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019075635A Division JP6788062B2 (ja) | 2012-07-20 | 2019-04-11 | 抗炎症活性を有するペプチド、及びそれを含む組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017158561A JP2017158561A (ja) | 2017-09-14 |
| JP2017158561A5 true JP2017158561A5 (enExample) | 2018-11-22 |
| JP6514259B2 JP6514259B2 (ja) | 2019-05-15 |
Family
ID=47882177
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015521997A Active JP6352911B2 (ja) | 2012-07-20 | 2013-03-15 | 抗炎症活性を有するペプチド、及びそれを含む組成物 |
| JP2017077422A Active JP6514259B2 (ja) | 2012-07-20 | 2017-04-10 | 抗炎症活性を有するペプチド、及びそれを含む組成物 |
| JP2019075635A Active JP6788062B2 (ja) | 2012-07-20 | 2019-04-11 | 抗炎症活性を有するペプチド、及びそれを含む組成物 |
| JP2020181780A Active JP7128246B2 (ja) | 2012-07-20 | 2020-10-29 | 抗炎症活性を有するペプチド、及びそれを含む組成物 |
| JP2022130519A Active JP7440581B2 (ja) | 2012-07-20 | 2022-08-18 | 抗炎症活性を有するペプチド、及びそれを含む組成物 |
| JP2024021407A Active JP7741218B2 (ja) | 2012-07-20 | 2024-02-15 | 抗炎症活性を有するペプチド、及びそれを含む組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015521997A Active JP6352911B2 (ja) | 2012-07-20 | 2013-03-15 | 抗炎症活性を有するペプチド、及びそれを含む組成物 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019075635A Active JP6788062B2 (ja) | 2012-07-20 | 2019-04-11 | 抗炎症活性を有するペプチド、及びそれを含む組成物 |
| JP2020181780A Active JP7128246B2 (ja) | 2012-07-20 | 2020-10-29 | 抗炎症活性を有するペプチド、及びそれを含む組成物 |
| JP2022130519A Active JP7440581B2 (ja) | 2012-07-20 | 2022-08-18 | 抗炎症活性を有するペプチド、及びそれを含む組成物 |
| JP2024021407A Active JP7741218B2 (ja) | 2012-07-20 | 2024-02-15 | 抗炎症活性を有するペプチド、及びそれを含む組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (6) | US20150125438A1 (enExample) |
| EP (3) | EP3428182B1 (enExample) |
| JP (6) | JP6352911B2 (enExample) |
| KR (2) | KR102302392B1 (enExample) |
| CN (3) | CN117551631A (enExample) |
| ES (2) | ES2693321T3 (enExample) |
| TW (6) | TWI700290B (enExample) |
| WO (1) | WO2014012683A1 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9320058D0 (en) | 1993-09-29 | 1993-11-17 | Gillette Co | Savety razors |
| ES3046661T3 (en) | 2012-05-11 | 2025-12-02 | Gemvax & Kael Co Ltd | Anti-inflammatory peptides and composition comprising the same |
| KR101799904B1 (ko) | 2012-07-11 | 2017-11-22 | 주식회사 젬백스앤카엘 | 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물 |
| US20150125438A1 (en) | 2012-07-20 | 2015-05-07 | Sang Jae Kim | Anti-Inflammatory Peptides and Composition Comprising the Same |
| EP2899201B1 (en) | 2012-09-19 | 2019-09-11 | Gemvax & Kael Co., Ltd. | Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate |
| WO2014046478A1 (ko) | 2012-09-19 | 2014-03-27 | 주식회사 카엘젬백스 | 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물 |
| WO2014151736A1 (en) * | 2013-03-15 | 2014-09-25 | Promega Corporation | Activation of bioluminescence by structural complementation |
| EP4063863A1 (en) | 2013-06-07 | 2022-09-28 | Gemvax & Kael Co., Ltd. | Gv1001, gemcitabine and capecitabine for use in the treatment of pancreatic cancer in high eotaxin baseline level patients |
| TWI539960B (zh) | 2013-06-21 | 2016-07-01 | 凱爾傑姆維克斯有限公司 | 激素分泌調節劑、包括其的組成物以及其用途 |
| EP3020724A4 (en) * | 2013-07-12 | 2017-01-18 | Gemvax & Kael Co., Ltd. | Cell-penetrating peptide and conjugate comprising same |
| KR102359396B1 (ko) | 2013-11-22 | 2022-02-08 | 주식회사 젬백스앤카엘 | 혈관 신생 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물 |
| WO2015093854A1 (ko) | 2013-12-17 | 2015-06-25 | 주식회사 카엘젬백스 | 전립선 암 치료용 조성물 |
| KR102373603B1 (ko) * | 2014-04-11 | 2022-03-14 | 주식회사 젬백스앤카엘 | 섬유증 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물 |
| WO2015167067A1 (ko) * | 2014-04-30 | 2015-11-05 | 주식회사 카엘젬백스 | 장기, 조직 또는 세포 이식용 조성물, 키트 및 이식 방법 |
| EP3193906B1 (en) * | 2014-09-18 | 2020-11-11 | The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of Holy and Undiv. Trinity of Queen Elizabeth near Dublin | Use of peptide inhibitors of il-36 proteolytic processing for the treatment and/or reduction of inflammation |
| KR102413243B1 (ko) | 2014-12-23 | 2022-06-27 | 주식회사 젬백스앤카엘 | 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물 |
| ES2799511T3 (es) | 2015-02-27 | 2020-12-18 | Gemvax & Kael Co Ltd | Péptido para prevenir la pérdida de audición, y composición que lo comprende |
| KR101662438B1 (ko) * | 2015-04-07 | 2016-10-04 | 가톨릭대학교 산학협력단 | X형 구조의 dna를 유효성분으로 포함하는 아토피 피부염 예방 또는 치료용 조성물 |
| KR101734529B1 (ko) | 2015-05-08 | 2017-05-11 | 건국대학교 산학협력단 | 패혈증 치료제의 스크리닝 방법 및 패혈증 치료용 약학 조성물 |
| WO2016190660A1 (ko) | 2015-05-26 | 2016-12-01 | 주식회사 젬백스앤카엘 | 신규 펩티드 및 이를 포함한 조성물 |
| US11015179B2 (en) | 2015-07-02 | 2021-05-25 | Gemvax & Kael Co., Ltd. | Peptide having anti-viral effect and composition containing same |
| AU2016316774A1 (en) | 2015-08-28 | 2018-03-22 | The Medical College Of Wisconsin, Inc. | Peptide inhibitors of telomerase translocation and therapeutic uses thereof |
| AU2016321333A1 (en) * | 2015-09-09 | 2018-04-26 | Psomagen, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with cerebro-craniofacial health |
| US10898540B2 (en) | 2016-04-07 | 2021-01-26 | Gem Vax & KAEL Co., Ltd. | Peptide having effects of increasing telomerase activity and extending telomere, and composition containing same |
| KR101831888B1 (ko) * | 2016-04-15 | 2018-04-16 | (주)케어젠 | 항염증 활성을 갖는 펩타이드 및 이의 용도 |
| KR101887577B1 (ko) * | 2016-10-19 | 2018-09-10 | (주)케어젠 | 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도 |
| AU2017382037B2 (en) * | 2016-12-22 | 2022-03-10 | Centre Hospitalier Universitaire De Montpellier | New stapled-peptides and uses thereof |
| JP6601849B2 (ja) * | 2017-08-21 | 2019-11-06 | 株式会社大一商会 | 遊技機 |
| JP6601848B2 (ja) * | 2017-08-21 | 2019-11-06 | 株式会社大一商会 | 遊技機 |
| KR102092843B1 (ko) * | 2018-08-30 | 2020-03-24 | 충남대학교 산학협력단 | 암 예방 또는 치료용 펩타이드 및 이의 용도 |
| KR102274658B1 (ko) * | 2018-11-16 | 2021-07-09 | 주식회사 카인사이언스 | 염증성 피부질환 치료용 펩타이드 및 이의 용도 |
| KR102032945B1 (ko) * | 2018-12-03 | 2019-10-16 | 순천대학교 산학협력단 | 항염증 활성을 나타내는 펩타이드 및 이를 유효성분으로 포함하는 항염증용 조성물 |
| KR102146937B1 (ko) * | 2018-12-11 | 2020-08-21 | 대한민국 | 왕사마귀로부터 유래된 테노데라신-1 펩타이드, 이를 유효성분으로 포함하는 항균, 항진균 또는 항염증용 조성물 |
| KR102266613B1 (ko) * | 2020-09-21 | 2021-06-18 | 자안바이오 주식회사 | 항염증 활성을 갖는 신규한 펩티드 및 이의 용도 |
| EP4288149A1 (en) * | 2021-02-08 | 2023-12-13 | Bacoba AG | Treatment of skin disorders |
| WO2023214802A1 (ko) * | 2022-05-03 | 2023-11-09 | 한국생명공학연구원 | 신규 펩타이드 및 이의 항염 및 재생 용도 |
| KR102827929B1 (ko) * | 2023-01-26 | 2025-07-09 | ㈜에빅스젠 | 신규한 뇌 질환 치료제 및 이의 용도 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1523965A (en) * | 1976-03-19 | 1978-09-06 | Ici Ltd | Pharmaceutical compositions containing steroids |
| DE4330664A1 (de) * | 1993-09-10 | 1995-03-16 | Beiersdorf Ag | Verwendungen von Pflanzenölen |
| ATE308554T1 (de) * | 1994-07-07 | 2005-11-15 | Geron Corp | Säugetier-telomerase |
| SK176598A3 (en) * | 1996-06-25 | 2000-06-12 | Pfizer | Indazole derivatives, pharmaceutical composition on their base and methods of treatment |
| CN102021153B (zh) * | 1996-10-01 | 2016-05-25 | 杰龙公司 | 人类的端粒酶催化亚单位 |
| US6610839B1 (en) * | 1997-08-14 | 2003-08-26 | Geron Corporation | Promoter for telomerase reverse transcriptase |
| KR100581990B1 (ko) * | 1997-07-01 | 2006-05-23 | 캄비아 바이오시스템즈 엘엘씨 | 척추 동물 텔로머라제 유전자 및 단백질과 이의 용도 |
| US7030211B1 (en) | 1998-07-08 | 2006-04-18 | Gemvax As | Antigenic peptides derived from telomerase |
| US20030171280A1 (en) * | 2001-07-31 | 2003-09-11 | Soderstrom Karl Petter | Compositions and methods for modulation of immune responses |
| JP2005502335A (ja) * | 2001-08-08 | 2005-01-27 | インサイト・ゲノミックス・インコーポレイテッド | 細胞成長、分化および細胞死関連タンパク質 |
| US8492438B2 (en) * | 2002-04-26 | 2013-07-23 | Asan Laboratories Company (Cayman), Limited | Treatment skin disorders |
| AU2004236708A1 (en) * | 2003-05-01 | 2004-11-18 | Musc Foundation For Research Development | An autologous upregulation mechanism allowing optimized cell type-specific and regulated gene expression cells |
| CN101011571A (zh) * | 2006-03-13 | 2007-08-08 | 上海交通大学医学院 | GADD45 β 蛋白及其抑制剂在类风湿关节炎中的应用 |
| CA2665816C (en) * | 2006-09-21 | 2016-07-12 | Vaxil Biotherapeutics Ltd. | Antigen specific multi epitope vaccines |
| MX2009003873A (es) * | 2006-10-12 | 2009-04-22 | Angeletti P Ist Richerche Bio | Proteina de fusion de transcriptasa inversa de telomerasa, nucleotidos que la codifican y usos de la misma. |
| WO2008142376A1 (en) | 2007-05-18 | 2008-11-27 | Inhibox Ltd. | Bicyclosulfonyl acid (bcsa) compounds and their use as therapeutic agents |
| WO2009025871A1 (en) * | 2007-08-23 | 2009-02-26 | University Of Medicine And Dentistry Of Nj | Telomerase reverse transcriptase variant |
| GB2455539B (en) | 2007-12-12 | 2012-01-18 | Cambridge Entpr Ltd | Anti-inflammatory compositions and combinations |
| WO2010003520A2 (en) | 2008-06-16 | 2010-01-14 | Genovax S.R.L. | Anti-tumor immunotherapy |
| US8252282B2 (en) * | 2008-06-19 | 2012-08-28 | University Of Medicine & Dentistry Of New Jersey | Nuclear telomerase reverse transcriptase variant |
| WO2010032322A1 (ja) | 2008-09-22 | 2010-03-25 | 日清ファルマ株式会社 | 抗炎症性ペプチド |
| US20110318380A1 (en) | 2008-10-01 | 2011-12-29 | Dako Denmark A/S | MHC Multimers in Cancer Vaccines and Immune Monitoring |
| ES2751092T3 (es) * | 2010-02-16 | 2020-03-30 | Ultimovacs Asa | Polipéptidos |
| KR101284772B1 (ko) | 2011-05-24 | 2013-07-17 | 정종문 | 항염증, 진통효과를 가지는 기능성 식품 조성물 |
| KR20120133661A (ko) | 2011-05-31 | 2012-12-11 | 주식회사 바이오포트코리아 | 아스타잔틴을 포함하는 항염증제 |
| ES3046661T3 (en) | 2012-05-11 | 2025-12-02 | Gemvax & Kael Co Ltd | Anti-inflammatory peptides and composition comprising the same |
| US20150125438A1 (en) | 2012-07-20 | 2015-05-07 | Sang Jae Kim | Anti-Inflammatory Peptides and Composition Comprising the Same |
| EP2899201B1 (en) | 2012-09-19 | 2019-09-11 | Gemvax & Kael Co., Ltd. | Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate |
| ES2743919T3 (es) | 2012-09-19 | 2020-02-21 | Gemvax & Kael Co Ltd | Péptido de penetración celular, conjugado que comprende el mismo y composición que comprende el conjugado |
| WO2014046478A1 (ko) | 2012-09-19 | 2014-03-27 | 주식회사 카엘젬백스 | 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물 |
| EP4063863A1 (en) * | 2013-06-07 | 2022-09-28 | Gemvax & Kael Co., Ltd. | Gv1001, gemcitabine and capecitabine for use in the treatment of pancreatic cancer in high eotaxin baseline level patients |
| EP3020724A4 (en) | 2013-07-12 | 2017-01-18 | Gemvax & Kael Co., Ltd. | Cell-penetrating peptide and conjugate comprising same |
| WO2016190660A1 (ko) | 2015-05-26 | 2016-12-01 | 주식회사 젬백스앤카엘 | 신규 펩티드 및 이를 포함한 조성물 |
| TW201718028A (zh) | 2015-10-13 | 2017-06-01 | 賽米克Ｉｐ有限責任公司 | Ve-鈣黏蛋白結合性生物結合物 |
-
2013
- 2013-03-05 US US14/400,322 patent/US20150125438A1/en not_active Abandoned
- 2013-03-15 KR KR1020207019525A patent/KR102302392B1/ko active Active
- 2013-03-15 WO PCT/EP2013/055326 patent/WO2014012683A1/en not_active Ceased
- 2013-03-15 CN CN202311502816.XA patent/CN117551631A/zh active Pending
- 2013-03-15 JP JP2015521997A patent/JP6352911B2/ja active Active
- 2013-03-15 EP EP18187426.4A patent/EP3428182B1/en active Active
- 2013-03-15 ES ES13709221T patent/ES2693321T3/es active Active
- 2013-03-15 KR KR1020147034319A patent/KR20150031413A/ko not_active Ceased
- 2013-03-15 EP EP13709221.9A patent/EP2875042B1/en active Active
- 2013-03-15 EP EP21162575.1A patent/EP3896078B1/en active Active
- 2013-03-15 ES ES18187426T patent/ES2871899T3/es active Active
- 2013-03-15 CN CN201910110866.0A patent/CN109777791B/zh active Active
- 2013-03-15 CN CN201380038045.1A patent/CN104470947B/zh active Active
- 2013-05-01 TW TW108101145A patent/TWI700290B/zh active
- 2013-05-01 TW TW113100053A patent/TW202417473A/zh unknown
- 2013-05-01 TW TW102115615A patent/TWI658141B/zh active
- 2013-05-01 TW TW111118818A patent/TWI836435B/zh active
- 2013-05-01 TW TW106121753A patent/TWI647311B/zh active
- 2013-05-01 TW TW109115548A patent/TWI779287B/zh active
-
2017
- 2017-04-05 US US15/479,746 patent/US20170275603A1/en not_active Abandoned
- 2017-04-10 JP JP2017077422A patent/JP6514259B2/ja active Active
-
2019
- 2019-04-11 JP JP2019075635A patent/JP6788062B2/ja active Active
-
2020
- 2020-01-17 US US16/746,018 patent/US20200140832A1/en not_active Abandoned
- 2020-03-13 US US16/818,001 patent/US11098294B2/en active Active
- 2020-10-29 JP JP2020181780A patent/JP7128246B2/ja active Active
-
2021
- 2021-07-30 US US17/389,671 patent/US11905536B2/en active Active
-
2022
- 2022-08-18 JP JP2022130519A patent/JP7440581B2/ja active Active
-
2024
- 2024-01-12 US US18/411,838 patent/US20240158768A1/en active Pending
- 2024-02-15 JP JP2024021407A patent/JP7741218B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017158561A5 (enExample) | ||
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| RU2017101705A (ru) | Фармацевтическая композиция, предназначенная для применения для предупреждения и/или лечения заболевания, которое развивается или прогрессирует вследствие снижения или утраты активности фактора свертывания крови viii и/или активированного фактора свертывания крови viii | |
| JP2015517488A5 (enExample) | ||
| JPWO2019156137A5 (enExample) | ||
| CN111344398A (zh) | 分离的重组溶瘤腺病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途 | |
| JP2016506416A5 (enExample) | ||
| JP2017503820A5 (enExample) | ||
| EA201992607A1 (ru) | Твердые формы берберина урсодезоксихолата, их композиции и способы | |
| RU2020126034A (ru) | Векторы фактора fviii на основе аденоассоциированных вирусов, соответствующие вирусные частицы и содержащие их терапевтические композиции | |
| JPWO2019107530A5 (enExample) | ||
| JP2013542185A5 (enExample) | ||
| MY201105A (en) | Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus | |
| CN110114083A (zh) | 一种预防和治疗脂肪肝的方法 | |
| JP2019533722A5 (enExample) | ||
| MY178445A (en) | Novel antibody binding to tfpi and composition comprising the same | |
| Liu et al. | Chrysin ameliorates influenza virus infection in the upper airways by repressing virus-induced cell cycle arrest and mitochondria-dependent apoptosis | |
| RU2016108808A (ru) | Терапевтическое применение vegf-c и ccbe1 | |
| EP4225382A4 (en) | ADMINISTRATION OF THERAPEUTIC ADENO-ASSOCIATED VIRUS FUKKUTIN-ASSOCIATED PROTEIN (FKRP) FOR THE TREATMENT OF DYSTROGLYCANOPATHY. DISORDERS INCLUDING LIMB GIRDLE 21 | |
| JP2019531293A5 (enExample) | ||
| EA201300421A1 (ru) | Комбинированная терапия для лечения инфекции hcv | |
| WO2020219766A8 (en) | Compositions useful in treatment of rett syndrome | |
| Ellerhoff et al. | Novel epi-virotherapeutic treatment of pancreatic cancer combining the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine virus | |
| WO2016090107A3 (en) | Treatment of hepatitis delta virus infection | |
| CN111417402A (zh) | 充分剂量条件下治疗乙肝病毒相关肝病的药物和方法 |